Clinical Trial

Neoadjuvant Lymph Node Targeted Immunotherapy in Cervical Cancer: a Feasibility Study (NEOLYNC)

Name: Neoadjuvant Lymph Node Targeted Immunotherapy in Cervical Cancer: a Feasibility Study (NEOLYNC) — clinical trial record (NCT07653503)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: NEOLYNC

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

We aim to determine feasibility, safety and efficacy of TDLN-targeted immune checkpoint inhibition in different doses (nivolumab) in patients with cervical cancer.

Trial Details

NCT Number	NCT07653503
Lead Sponsor	University Medical Center Groningen
Conditions	Cervical Carcinoma
Enrollment	12 participants
Start Date	2026-01-05
Primary Completion	2027-12-01 (estimated)
Study Completion	2027-12-01 (estimated)
Updated on ClinicalTrials.gov	2026-06-17